Baird Medical Investment Holdings Limited (BDMD)
NASDAQ: BDMD · Real-Time Price · USD
7.73
-3.38 (-30.42%)
At close: Jan 14, 2025, 4:00 PM
7.66
-0.07 (-0.91%)
After-hours: Jan 14, 2025, 7:25 PM EST
Company Description
Baird Medical Investment Holdings Limited, together with its subsidiaries develops and sells microwave ablation medical devices for minimally invasive tumor treatment in China.
The company’s medical devices are used for treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps.
Baird Medical Investment Holdings Limited was founded in 2012 and is headquartered in Guangzhou, China.
Baird Medical Investment Holdings Limited
| Country | China |
| Founded | 2012 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 148 |
| CEO | Haimei Wu |
Contact Details
Address: Room 202, 2/F, Baide Building Guangzhou, 510000 China | |
| Phone | 86 20 8218 5926 |
| Website | bairdmed.com |
Stock Details
| Ticker Symbol | BDMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001982444 |
| CUSIP Number | G0705H103 |
| ISIN Number | KYG0705H1039 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Haimei Wu | Chairwoman of the Board of Directors and Chief Executive Officer |
| Quan Qiu | Chief Administrative Officer and Executive Director |
| Wei Hou | Executive Director |
| Jie Li | Acting Chief Financial Officer |
| Rongjian Lu | Chief Technology Officer and Deputy GM |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 15, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Nov 1, 2024 | 6-K | Report of foreign issuer |
| Oct 9, 2024 | 20FR12B | Filing |
| Oct 2, 2024 | CERT | Certification by an exchange approving securities for listing |
| Oct 2, 2024 | 6-K | Report of foreign issuer |
| Oct 1, 2024 | 8-A12B | Registration of securities |
| Sep 6, 2024 | 425 | Filing |
| Sep 5, 2024 | EFFECT | Notice of Effectiveness |
| Sep 5, 2024 | 424B3 | Prospectus |